MedTrace Logo

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

NCT02131688 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.

Conditions

  • Malignant Lymphoma

Interventions

DRUG

Mitoxantrone Hydrochloride Liposome

Sponsors & Collaborators

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi, Ph.D · Cancer Hospital ,Chinese Academy of Mddical Sciences

Study Design

Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-08-31
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02131688 on ClinicalTrials.gov